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Introduction: The U.S. opioid epidemic has highlighted the need to identify patients at risk 
of opioid abuse and overdose. We initiated a novel emergency department- (ED) based 
interventional protocol to transition our superuser patients from the ED to an outpatient chronic 
pain program. The objective was to evaluate the protocol’s effect on superusers’ annual ED visits. 
Secondary outcomes included a quantitative evaluation of statewide opioid prescriptions for these 
patients, unique prescribers of controlled substances, and ancillary testing.
Methods: Patients were referred to the program with the following inclusion criteria: ≥ 6 visits 
per year to the ED; at least one visit identified by the attending physician as primarily driven by 
opioid-seeking behavior; and a review by a committee comprising ED administration and case 
management. Patients were referred to a pain management clinic and informed that they would 
no longer receive opioid prescriptions from visits to the ED for chronic pain complaints. Electronic 
medical record (EMR) alerts notified ED providers of the patient’s referral at subsequent visits. We 
analyzed one year of data pre- and post-referral.
Results: A total of 243 patients had one year of data post-referral for analysis. Median annual 
ED visits decreased from 14 to 4 (58% decrease, 95% CI [50 to 66]). We also found statistically 
significant decreases for these patients’ state prescription drug monitoring program (PDMP) opioid 
prescriptions (21 to 13), total unique controlled-substance prescribers (11 to 7), computed tomography 
imaging (2 to 0), radiographs (5 to 1), electrocardiograms (12 to 4), and labs run (47 to 13). 
Conclusion: This program and the EMR-based alerts were successful at decreasing local ED 
visits, annual opioid prescriptions, and hospital resource allocation for this population of patients. 
There is no evidence that these patients diverted their visits to neighboring EDs after being 
informed that they would not receive opioids at this hospital, as opioid prescriptions obtained by 
these patients decreased on a statewide level. This implies that individual ED protocols can have 
significant impact on the behavior of patients. [West J Emerg Med. 2017;18(5)894-902.]
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Population Health Research Capsule
What do we already know about this issue?
Opioid prescriptions and overdoses have 
increased significantly in the past 30 years. 
Superuser patients may use the Emergency 
Department (ED) as a source for opioids.
What was the research question?
Does ED referral to a pain management 
group – with subsequent EMR-based 
reminders to ED practitioners - decrease 
annual visits from superuser patients?
What was the major finding of the study?
Superuser patients had fewer overall ED 
visits after the intervention, decreasing 
annual visits from 14 to 4.
How does this improve population health?
Enrollment in a chronic pain program with 
EMR-based provider reminders appeared 
to decrease overall visits to the ED 
post-intervention.
INTRODUCTION
Background
In the early 1990s there was a concerted effort by 
the Veterans Health Administration (VHA) and The Joint 
Commission to target pain management with opioids.1 Pain 
quickly became the “fifth vital sign,” and opioid prescriptions 
escalated.2 Between 1999 and 2010, the marketing of opioids to 
pharmacists, hospitals, and doctors’ offices had quadrupled, and 
there was a 300% increase in the prescription of opioids in the 
U.S.3,4 With this dramatic increase in opioid prescribing behavior, 
a number of serious unintended consequences were noted. In 
2008, prescription opioids were estimated to be the direct cause 
for approximately 15,000 annual overdose deaths in the U.S., 
with that number almost doubling to 29,000 in 2014. 5,6Each 
opioid abuser incurs $20,546 more in annual healthcare costs 
than demographically similar controls.7 Direct healthcare costs of 
improper and non-medical opioid prescription use is estimated to 
be greater than $72 billion per year.3 
Importance
Emergency department (ED) visits related to prescription 
opioid abuse have risen dramatically from 173,000 in 2004 
to 416,000 in 2009 and now are over 500,000 annually.3,4,7 
Many efforts have been made to identify patients with 
drug-seeking behaviors as well as providers with aberrant 
prescribing practices.7-11 These include increased regulations 
on pain clinics, prescription threshold guidelines, controlled 
substance contracts, and the establishment of prescription drug 
monitoring programs (PDMP).
Goals of This Investigation
The purpose of this study was to examine and present 
the outcomes of a novel interventional chronic pain program 
established in a metropolitan ED. The protocol was designed 
to transition superuser opioid-seeking patients out of the 
ED and into a chronic taper-to-abstinence pain program. 
We primarily hypothesized that visits to the ED post-
referral would decrease. We hypothesized that secondary 
outcomes would similarly decrease, such as statewide opioid 
prescriptions, number of opioid prescribers, number of 
electrocardiographs (ECG) , laboratory tests, radiographs, and 
computed tomography (CT) imaging. 
METHODS
Study Design and Setting
This study is a retrospective analysis of a novel 
preexisting, administrative chronic pain management program 
at Methodist Hospital in Indianapolis, IN. This is an urban 
teaching hospital with an annual ED volume of approximately 
102,000 patients per year. Patients were drawn from the 
existing administrative database of frequent opioid recidivists 
who had been prospectively identified for inclusion into the 
program as outlined below. The study is designed as a one-
way crossover intervention, with patients serving as their 
own controls in the year prior to their referral in the program. 
The protocol was approved as an administrative policy four 
years prior to the collection of any research data. Research 
data gathering was separately approved and registered by 
the Indiana University (IU) Institutional Review Board 
(1409177708).
Selection of Participants
Inclusion criteria into the chronic pain program were 
as follows: 1) Frequent use of the ED, defined as ≥ 6 visits 
per year; 2) At least one visit identified by the treating 
attending physician as primarily driven by opioid-seeking 
behavior; and 3) Chart review by ED administration and case 
management for evidence of ED misuse. Patients meeting 
all three of these criteria were referred to the chronic pain 
program unless they met exclusion criteria below. 
Exclusion criteria for the chronic pain program were 
preexisting chronic disease processes expected to cause 
frequent and uncontrollable visits to the ED, such as 
cancer or sickle cell disease. Pregnancy and age were not 
exclusion criteria. 
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Age (yrs)
Mean (range) 41 (18-67)
Gender
Female 151 (62%)
Race/ethnicity*
American Indian 1 (0.4%)
Asian 1 (0.4%)
Hawaiian/Pacific Islander 0 (0%)
Black 71 (29%)
White 169 (70%)
Other 0 (0%)
Hispanic 3 (1%)
Charleson comorbidity score
Median (IQR) 1 (0-1)
Table 1. Demographics with descriptive statistics.We excluded patients from the retrospective data analysis 
if they had not been part of the chronic pain program for at 
least a year. These patients would not have a full year of data 
post-intervention to compare to the year prior. Demographic 
characteristics of the participants can be found in Table 1.
Interventions
After medical director approval, patients were referred to 
a free, outpatient taper-to-abstinence pain management clinic. 
A chronic pain management and addiction specialist runs the 
clinic. Patients were notified by an administrator either in 
person at their next visit or by telephone that they had been 
referred into a chronic pain program. They were also informed 
that they would no longer routinely receive opioids or opioid 
prescriptions for their chronic painful conditions from the 
ED. Additionally, they received written instructions and 
information either in person or by certified mail. 
Exceptions were made for acute pain not related to a 
chronic condition, such as new fractures. Those patients non-
compliant with follow-up with the pain management program 
were contacted on subsequent ED visits and referred again. 
Treatment with opioids, both parenteral and prescribed, 
remained at the discretion of the treating ED provider, with 
a reminder in place that the patient had already been given 
outpatient follow-up.
To reinforce the program to emergency physicians, an 
electronic medical record- (EMR) based notification was 
implemented, which was activated any time the patient arrived 
in the ED. This notification is three-fold. On the ED tracking 
screen, a flag is placed to alert providers to the patient’s 
referral to the program. Upon opening the patient’s chart, a 
pop-up alert indicates the patient’s chronic pain management, 
with instructions to refer to the case management notes for 
specific details. If opioids are chosen as a treatment modality, 
a separate notification activates to ensure that the provider is 
aware that the patient has been referred to pain management.
Methods and Measurements
We collected and managed study data using REDCap 
electronic data capture tools hosted at IU.12 REDCap 
(Research Electronic Data Capture) is a secure, web-based 
application designed to support data capture for research 
studies, providing the following: 1) an intuitive interface 
for validated data entry; 2) audit trails for tracking data 
manipulation and export procedures; 3) automated export 
procedures for seamless data downloads to common 
statistical packages; and 4) procedures for importing data 
from external sources.
Data regarding controlled substance prescriptions pre- and 
post-referral into the program was captured via the Indiana 
Board of Pharmacy Prescription Monitoring System or 
INspect. All pharmacies are mandated to report any controlled 
substance filled to this database. The few exceptions are entities 
and clinics governed by federal regulations (the VHA, as well as 
methadone and suboxone clinics). Data included in the database 
are the following: Patient demographics (name, date of birth, 
address), prescriber, prescriber demographics, date of prescription 
filled, pharmacy demographics, prescribed substance, strength, 
quantity, intended days, and date written. We obtained data 
regarding ED visits pre- and post-referral via Indiana University 
Health’s (IUH) EMR (Cerner), which connects approximately 
32 hospitals, rehabilitation facilities, and clinics across the 
greater Indianapolis area. Data were collected on a data 
abstraction form by blinded, trained abstractors. As this was 
a retrospective chart review, a random sample of 10% of the 
charts was reassessed by one of the investigators (reassessed 
by one of the investigators [ZPK]). We performed a kappa 
analysis for the primary outcome, which was found to be 0.91, 
indicating excellent inter-rater reliability.
Outcomes 
The primary outcome of interest was the difference between 
annual ED visits to an annual ED visits to an IUH ED pre- and 
post-referral into the chronic pain program. Secondary outcomes 
included their statewide opioid prescriptions, number of unique 
prescribers of controlled substances, as well as ancillary testing: 
number of ECGs, laboratory tests, radiographs, and CTs.
Analysis
We performed statistical analysis using the R statistical 
software package with the Rstudio frontend (Foundation for 
Open Access Statistics, Boston MA). Descriptive analyses are 
reported where appropriate. Mean values are reported for normal 
data with standard deviations, with significance between results 
analyzed with Student’s t-test for unpaired values and Student’s 
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paired t-test for paired values. Non-normal data is reported 
in medians with interquartile ranges (IQR), with significance 
analyzed by Mann-Whitney U test for unpaired values and 
Wilcoxon signed-rank test for paired values. As most of the 
data is non-normal, the primary analysis method used was the 
Wilcoxon signed-rank test for paired medians. We calculated data 
to a significance of α=0.05 and β=0.20 where appropriate. There 
was no formal sample size calculated, as this was a retrospective 
study performed on all eligible existing patients in the program. 
A priori to capture and analysis of our data, we identified annual 
ED visits as our primary outcome, with secondary outcomes as 
described in outcomes and analysis.
RESULTS
Characteristics of Study Subjects
At the time of data gathering, 278 patients had been referred 
into the program. Of those patients, 243 had been in the program 
for one year or greater, and therefore had 12 months of data both 
pre- and post-intervention. Demographics of the participants are 
shown in Table 1. Mean age of the study group was 41, 62% of 
which were female. These were predominantly White patients 
(70%), while 29% were Black, and the remainder American 
Indian, Asian, and Hispanic. The cohort was healthy in general 
with a median Charleson Comorbidity score of 1. The most 
common comorbidities in this cohort were chronic pulmonary 
disease (asthma or COPD) n=23, and diabetes without end-organ 
dysfunction n=23.
The primary outcome was the number of ED visits pre- and 
post-intervention. This data is represented visually in Figure.
Given the skewness of the data, our data is primarily 
reported in median values, although mean values are also 
reported in Table 2.
Median ED visits to hospitals in our health system decreased 
from 14 to 4 (58% decrease, 95% CI [50 to 66]). We evaluated 
visits as paired data, with each patient serving as their own 
control. Mean visits decreased from 19 to 6, implying a rightward 
skewness of the data. When assessing the highest quartile, we 
found that median visits decreased from 25 to eight. The outlier 
patient decreased annual visits to our ED from 131 to 13.
Secondary outcomes were similarly significant. Total 
median number of opioid prescriptions filled statewide 
decreased from 21 to 13 (30% decrease, 95% CI [24 to 37]), 
as did median number of statewide prescribers 11 to seven 
(31% decrease, 95% CI [23 to 38]). 
DISCUSSION
In this study, we present the outcomes of a novel, 
administratively instituted “no-opioid” policy for 243 patients at 
a large metropolitan hospital. These patients had been identified 
as over-using the ED, primarily to obtain opioids for chronic 
pain. It has been previously estimated that approximately 5% of 
patients account for 25% of all ED visits, and chronic pain and 
addiction is often a driving force behind this recidivism.13 This 
population is at high risk for opioid overdose and subsequent 
hospitalization, and a major component of their access to opioids 
is a “revolving door” of prescribers.14 
Our study demonstrated decreased visits to our facility 
from these patients by 58%, a decrease in the number of unique 
prescribers for their controlled substances by 31%, and a decrease 
in the number of prescriptions these patients received statewide 
by 30%. Of note, our intervention appears to have decreased 
overall opioid prescriptions and prescribers statewide for these 
enrolled patients, despite being implemented at only one facility. 
We believe that this implies that there is a significant degree of 
local bias in care for these patients – that is, patients preferentially 
seek care at the closest ED to their home. When access to opioids 
is fettered at that site, these patients did not appear to supplement 
by simply visiting neighboring EDs. This may be the understated 
strength of our administrative policy; our results imply that our 
ED was a major source of these patients’ legal access to opioids. 
Further, when opioid prescriptions are restricted from the ED, this 
patient population decreases ED visit frequency.
To date, there is no standardized definition of frequent users 
of the ED. Various authors have proposed anywhere from 3-10 
visits as “frequent.”15-18 Our protocol used ≥ 6 visits per year as 
the cutoff, although the median number of visits in our study 
population overall was 14 per year, with the highest 10% of our 
study group visiting 52 times per year. This population can be 
very difficult to manage; psychosocial factors, addiction, opioid 
hyperalgesia, and personality traits influence their presentation. 
Further, emergency physicians often treat acute flares of chronic 
pain with a “short course” of opioids, which may reinforce the 
patient’s ED recidivism.
Several researchers have evaluated ED pain protocols prior 
to this study.17-19 Our study is unique for three main reasons: 
the large number of patients included, the analysis of repeat 
ED visits, and the EMR-based reminders to providers. To date, 
no study has evaluated a policy such as ours on such a scale, 
nor have studies evaluated the granular effect on resource 
expenditure. We believe the success of this protocol was wholly 
dependent on strong administrative support for the policy and the 
repeated EMR-based alerts. 
With regards to the first point, emergency providers 
often feel obligated to acquiesce to patient demands for fear 
of lowered patient satisfaction scores, or simply to avoid a 
complaint.2,20 However, recent studies have called into question 
this assumption, with at least one study by Schwartz et al. 
finding no association between opioid administration and patient 
satisfaction. 2,21-24Germaine to this point, recent evidence has 
demonstrated that increasing patient satisfaction scores are 
correlated with increased prescription drug expenses, increased 
healthcare expenditures and increased mortality.25 It is of 
paramount importance to provide medically appropriate care for 
patients, which may contrast with the goals of ED superusers. 
This subset of patients often requests unnecessary treatments, 
inappropriate prescriptions, or may simply use the ED as a food 
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Median (IQR) Mean Min^ - Max Percentage decrease (95% CI)
Number of ED visits
Pre 14 (8 – 25) 19 0 – 131 58 (50 to 66)
Post 4 (2 – 8) 6 0 – 58
Number of opioid prescriptions
Pre 21 (12 – 30) 23 0 – 105 30 (24 to 37)
Post 13 (5 – 24) 16 0 – 103
Number of prescribers
Pre 11 (7 - 16) 13 0 – 45 31 (23 to 38)
Post 7 (3 – 12) 9 0 – 43
Number of pharmacies used
Pre 6 (3 – 9) 7 0 – 34 29 (14 to 36)
Post 5 (2 – 7) 5 0 – 17
Number of lab draws
Pre 47 (17 – 101) 59 0 – 175 46 (36 to 57)
Post 13 (4 – 40) 31 0 – 184
Number of radiographs
Pre 5 (2 – 10) 8 0 – 64 44 (38 to 56)
Post 1 (0 – 5) 3 0 – 28
Number of CTs
Pre 2 (1 – 5) 4 0 – 32 63 (50 to 75)
Post 0 (0 – 2) 1 0 – 16
Number of ECGs
Pre 4 (1 – 12) 12 0 – 158 50 (38 to 67)
Post 2 (0 – 4) 4 0 – 49
Number of clinic visits
Pre 1 (0 – 5) 4 0 – 30 13 (-13 to 38)
Post 1 (0 – 4) 3 0 – 37
Number of hospitalizations
Pre 0 (0 – 1) 1 0 – 16 *
Post 0 (0 – 1) 0 0 – 7
Number of hospital days
Pre 0 (0 – 5) 7 0 – 207 85 (57 to 129)
Post 0 (0 – 0) 2 0 – 75
CT, computerized tomography; ED, emergency department; ECG, electrodiogram; IQR, interquartile range.
Rank test for median value.
^No minimum number of prescriptions required for referral. 8 patients unable to be found in EMR.
*Unable to compute secondary to divide by zero errors.
Table 2.Pre-post results for patients in the chronic pain program at one year.
and bed source. Thus, we feel that strong administrative support 
for a policy such as ours is critical.
As only a handful of patients followed up with the pain 
management clinic, this component of the intervention is unlikely 
to have changed ED visit frequency or prescription volume. 
Instead, the authors believe that the EMR-based reminders to 
physicians were the key component. These reminders occurred 
at every visit for each provider who interacted with the patient. 
Thus, prior to the administration or prescription of an opioid, 
the EMR reinforced the behavior of physicians and therefore 
patients. Many hospitals use a provider-initiated system for 
opioid management; that is, a provider must go looking for a care 
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management note, chronic pain policy, or must do a chart review 
manually.19 While accessing the state PDMP is encouraged before 
prescription of controlled substances, this typically requires a 
provider to leave the EMR and log into a separate system, which 
may hinder its use. 
Our EMR-based alerts were active, informing the patient’s 
ED provider of their chronic pain referral at every visit. When a 
patient’s chart is initially accessed at each visit, a reminder screen 
is displayed prior to chart access and order entry. This ensured 
that every provider who interacted with the patient was aware 
of the referral to the clinic. A secondary alert was triggered if 
providers ordered opioids.  
Ancillary testing decreased proportionally to the decrease 
in ED visits. If our intervention had biased physicians against 
these patients, causing physicians to assume that they were never 
“sick,” one would expect a comparatively greater decrease in 
the quantity of ancillary services used. Instead, there was strong 
correlation between both the decrease in ED visits and most of 
the secondary outcome variables, implying that these patients 
received the same amount of testing at each visit. To a degree, 
this is surprising; if a patient routinely presents with opioid-
seeking behavior, one would plausibly expect providers to 
decrease testing.
Of all 278 patients referred into the program, to date only 
seven have followed up with the referral outpatient clinic. Of 
these, only three have continued to follow up with the clinic, 
and the other four were discharged for noncompliance with 
controlled substance covenants. The remaining 271 patients either 
already had a primary care physician or missed all scheduled 
appointments with the clinic. We posit that this extremely poor 
Figure. Pre- and post-intervention frequency (number of patients) of annual visits by patients identified as over-users of the emergency 
department (ED).
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compliance is a direct function of the patient population included 
in our protocol; prior to referral in the protocol these patients had 
a 14:1 median ratio of ED visits to clinic visits. Our chronic pain 
clinic ensured that these patients had guaranteed follow-up for 
their chronic pain, and thus the ED was no longer an acceptable 
mechanism to fill this need.
There has been much research into maintenance 
therapy, adjunct therapy, and replacement therapy for opioid 
cessation.26-33 Unfortunately these clinics and therapies are 
often expensive, and due to the nature of the patients enrolled 
in this study, many had no resources or had already violated a 
pain contract. Thus, we identified a provider who was willing 
to see all of these patients free of charge, provided they were 
willing to wean to abstinence. Recent research has identified 
success with ED-initiated buprenorphine treatment as compared 
to intervention or referral to community resources.27 Our 
intervention was initiated without financial support; if possible, 
we would recommend that significant support in the form of 
social work, case management, and addiction specialists be 
provided to this vulnerable population.
One of our main concerns is that when cut off from a source 
of opioids, these patients may resort to illicit methods to supply 
their addiction. Recently there was an HIV outbreak in Southern 
Indiana among Opana (oxymorphone) users who were sharing 
needles to inject their prescriptions.34 While the risk of illicitly 
obtaining opioids is a major public health concern, the authors do 
not feel that this is an appropriate rationale for the ED to provide 
unfettered access to these medicines. Instead, we believe that the 
revolving door of the ED contributes to the problem. Future work 
is planned to aggressively support these patients with addiction 
management, social work, case management, and replacement 
therapy.
LIMITATIONS
There are several limitations to this study. This was 
a retrospective observational analysis of a preexisting 
administrative database at a large metropolitan hospital, which 
is part of a wide-reaching health system. While the data itself 
were not prospectively collected, the administrative protocol 
was performed in a prospective fashion. Thus, this study was a 
retrospective analysis of a prospective protocol, which we feel 
improved the robustness of the data. However, fundamentally this 
study was a retrospective review of existing data, and limitations 
exist for this form of study protocol. There is a potential 
for sampling bias in any retrospective review, although our 
abstractors followed strict rules and were transcribing concrete 
data points. We do note that we were unable to blind abstractors, 
but given the cohort nature of the study, all patients were “case” 
and blinding would be impossible. 
While the EMR connects most of the hospitals in 
our healthcare system, we were unable to assess visits 
at most urgent visit centers, or EDs within other health 
systems. However, the use of our state PDMP does act as a 
surrogate for whether subjects simply shifted their ED use 
to other health systems. We were unable to determine total 
morphine equivalents for our patients. Thus, the decrease in 
annual prescriptions may in fact represent consolidation of 
prescriptions to fewer providers, with increased pill quantities 
per prescription.  As there was no interview component to this 
study, we cannot determine if these patients went on to use 
illicit drugs at an increased rate.
One potential confounder is the increased national 
attention on restriction of opioid prescription at the same 
time as the study period. However, the study authors feel that 
it is unlikely that national attention alone resulted in a 58% 
decrease in opioid prescriptions for these patients.
A second confounder may be a natural decrease in opioid 
usage as painful conditions improve. However, prior studies 
have demonstrated that patients on long-term opioid therapy 
are unlikely to discontinue usage.35,36 Thus, we conclude 
that our intervention was the cause for the decreased overall 
prescription rate.
CONCLUSION
In summary, this study demonstrates the efficacy of an 
interventional protocol intended to decrease ED visits among 
ED superusers. These patients were selected as those who 
frequently presented for the primary purpose of obtaining 
opioids for chronic pain. While only a handful took advantage 
of the chronic pain clinic to which they were referred, our 
protocol resulted in a decrease in ED visits, fewer statewide 
opioid prescriptions for the cohort, and less ancillary testing 
such as ECGs, CTs and radiographs. Implementing this protocol 
is fairly straightforward, requiring only an EMR flag and a 
task force willing to steward the database. We believe that this 
protocol streamlines patient care, decreases unnecessary visits 
to the ED, improves patient safety and can be one tool to help 
EDs combat our current opioid epidemic.
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